Clinical Trial: A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710430) titled 'A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty' on July 06.

Brief Summary: A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Central Precocious Puberty

Intervention: DRUG: Leuprorelin

Leuprorelin will be administered every 4 weeks.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: LG Chem

Published by HT Digital Content Services with permission ...